NFKB1 and Peritoneal Fibrosis: However, the administration of parthenolide, a NF-κB inhibitor, has been shown to reduce inflammation and peritoneal fibrosis (PF) through the NF-κB/TGF-β/Smad pathway, thereby reducing the level of IL-6, TNF-α, and MCP-1 (61).